Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Liu

Showing results (311-320 of 361) with videos related to

Pageof 37
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
The Oncologist|July 10, 2024
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumorsDan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerRafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
The Oncologist|April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)Adel Mandl, Ruizhe Chen, Satya Das, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerJ J Lin, S V Liu, C E McCoach, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Cancer Research|October 1, 2021
Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential TherapyJunyu Yang, Chong Gao, Miao Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Pageof 37

Showing results (311-320 of 361) with videos related to

Sort By:
Pageof 37
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
The Oncologist|July 10, 2024
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumorsDan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerRafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
The Oncologist|April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)Adel Mandl, Ruizhe Chen, Satya Das, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerJ J Lin, S V Liu, C E McCoach, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Cancer Research|October 1, 2021
Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential TherapyJunyu Yang, Chong Gao, Miao Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Pageof 37